Patent ID: 8580519
Filing Date: 2013-11-12
Classification: G01N

Abstract:
1. A method of monitoring whether or not a cancer is responsive to a melanoma cancer therapy in an individual in need of therapy for melanoma and that has been diagnosed with melanoma, comprising: (1) determining the level of Hsp90 in the plasma or serum of the individual in need of therapy for melanoma prior to administration of the melanoma cancer therapy; (2) administering to the individual a desired dosage of the melanoma cancer therapy; (3) determining the level of Hsp90 in the plasma or serum of the individual following administration of the melanoma cancer therapy; (4) determining whether there is an increase in the level of Hsp90 in step (3) compared to step (1); and (5) classifying an individual as being responsive to the melanoma cancer therapy when there is an increase in the level of Hsp90, wherein the melanoma cancer therapy is a Hsp90-interacting therapy comprising an inhibitor of Hsp90 comprising one or more benzoquinoid ansamycins.